Teva
- All
- News
- Videos
-
Dr Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer
Erez Israeli, the former President and CEO of Enzymotec, will join Dr Reddy's Laboratories on April 2 as chief operating officer
-
Viagra's Own Generic, Cheaper Version By Pfizer To Hit Markets Soon
Just before other generic versions could hit the market, Pfizer came out with his own generic version of Viagra. This will help Pfizer Inc. avoiding the large amount of sales drop after markets will be flooded with numerous generic and cheaper versions of the impotence pill.
-
Teva Names Dipankar Bhattacharjee As Generics Group Head, Replacing Olafsson
Teva on Monday reaffirmed its full-year 2016 outlook of revenues of $21.6-$21.9 billion and adjusted earnings per share of $5.10-$5.20.
-
Aurobindo Arm To Acquire Select Products In France From Teva
Aurobindo Pharma has inked a pact to acquire select commercial products in France from Teva for an undisclosed amount.
-
Teva To Sell Allergan's Generics Business In UK, Ireland To Intas Pharmaceuticals
Greenhill & Co is Teva's financial adviser, while Rothschild & Co is advising Intas Pharmaceuticals.
-
Aurobindo Pharma Gains On Buzz Of Big UK Acquisition
Aurobindo Pharma shares gained over 1 per cent on Monday after a news report said that the Indian pharma company is a frontrunner to buy Teva Pharmaceutical's UK business, which had revenue of around $300 million last fiscal.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Dr Reddy's Completes Acquisition Of Products From Teva Pharma
Dr Reddy's Laboratories on Wednesday said it has successfully completed the $350-million (around Rs 2,300 crore) acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
-
Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva
Dr Reddy's laboratories, Cipla and Aurobindo Pharma are among 11 firms that may acquire 79 existing and future drugs from Teva Pharmaceuticals as part of the condition set by the US Federal Trade Commission for $40.5 billion Teva-Allegran deal.
-
Zydus Healthcare Buys 2 New Drug Applications From Teva
Zydus Healthcare, a subsidiary of Cadila Healthcare, today said it has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Dr Reddy's To Buy Eight Products In US For $350 Million
The portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business, the Hyderabad-based firm said.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Orchid Gets Final Nod from USFDA for Parkinson's Drug
Chennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets used in the treatment of Parkinson's disease.
-
Dr Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer
Erez Israeli, the former President and CEO of Enzymotec, will join Dr Reddy's Laboratories on April 2 as chief operating officer
-
Viagra's Own Generic, Cheaper Version By Pfizer To Hit Markets Soon
Just before other generic versions could hit the market, Pfizer came out with his own generic version of Viagra. This will help Pfizer Inc. avoiding the large amount of sales drop after markets will be flooded with numerous generic and cheaper versions of the impotence pill.
-
Teva Names Dipankar Bhattacharjee As Generics Group Head, Replacing Olafsson
Teva on Monday reaffirmed its full-year 2016 outlook of revenues of $21.6-$21.9 billion and adjusted earnings per share of $5.10-$5.20.
-
Aurobindo Arm To Acquire Select Products In France From Teva
Aurobindo Pharma has inked a pact to acquire select commercial products in France from Teva for an undisclosed amount.
-
Teva To Sell Allergan's Generics Business In UK, Ireland To Intas Pharmaceuticals
Greenhill & Co is Teva's financial adviser, while Rothschild & Co is advising Intas Pharmaceuticals.
-
Aurobindo Pharma Gains On Buzz Of Big UK Acquisition
Aurobindo Pharma shares gained over 1 per cent on Monday after a news report said that the Indian pharma company is a frontrunner to buy Teva Pharmaceutical's UK business, which had revenue of around $300 million last fiscal.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Dr Reddy's Completes Acquisition Of Products From Teva Pharma
Dr Reddy's Laboratories on Wednesday said it has successfully completed the $350-million (around Rs 2,300 crore) acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
-
Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva
Dr Reddy's laboratories, Cipla and Aurobindo Pharma are among 11 firms that may acquire 79 existing and future drugs from Teva Pharmaceuticals as part of the condition set by the US Federal Trade Commission for $40.5 billion Teva-Allegran deal.
-
Zydus Healthcare Buys 2 New Drug Applications From Teva
Zydus Healthcare, a subsidiary of Cadila Healthcare, today said it has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.
-
Dr Reddy's Laboratories To Buy 8 Drugs From Teva Pharmaceutical, Shares Gain
The combined sales of the branded versions of the products in the US is around $3.5 billion, Dr Reddy's added.
-
Dr Reddy's To Buy Eight Products In US For $350 Million
The portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business, the Hyderabad-based firm said.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
Orchid Gets Final Nod from USFDA for Parkinson's Drug
Chennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets used in the treatment of Parkinson's disease.
